医学
麻醉
氯胺酮
术后疼痛
胃肠功能
外科
腹部外科
随机对照试验
妇科手术
腹腔镜检查
作者
Tianzhuo Zhang,Zhijie Yue,Ling Yu,Shuo Li,Yining Xie,Jin Wei,Mengge Wu,Honglei Liu,Hongyu Tan
出处
期刊:BMC Surgery
[Springer Nature]
日期:2023-03-30
卷期号:23 (1)
被引量:7
标识
DOI:10.1186/s12893-023-01973-0
摘要
Background This prospective randomized controlled study was designed to evaluate the effect of S-ketamine with sufentanil given intraoperatively and postoperatively on recovery of gastrointestinal (GI) function and postoperative pain in gynecological patients undergoing open abdomen surgery. Methods One hundred gynecological patients undergoing open abdomen surgery were randomized into an S-ketamine group (group S) or placebo group (0.9% saline; group C). Anesthesia was maintained with S-ketamine, sevoflurane, and remifentanil-propofol target-controlled infusion in group S and with sevoflurane and remifentanil-propofol target-controlled infusion in group C. All patients were connected to patient-controlled intravenous analgesia (PCIA) pump at the end of the surgery with sufentanil, ketorolac tromethamine, and tropisetron in group C and additional S-ketamine in group S. The primary outcome was the time of first postoperative flatus, and the secondary outcome was postoperative pain score of patients. Postoperative sufentanil consumption within the first postoperative 24 h and adverse events such as nausea and vomiting were recorded. Results The time of first postoperative flatus in group S was significantly shorter (mean ± SD, 50.3 ± 13.5 h) than that in group C (mean ± SD, 56.5 ± 14.3 h, p = 0.042). The patient’s visual analog scale (VAS) pain score 24 h after surgery at rest was significantly lower in group S than in group C ( p = 0.032). There were no differences in sufentanil consumption within the first postoperative 24 h, postoperative complications related to PCIA between the two groups. Conclusions S-ketamine accelerated postoperative GI recovery and reduced 24 h postoperative pain in patients undergoing open gynecological surgery. Trial registration ChiCTR2200055180. Registered on 02/01/2022. It is a secondary analysis of the same trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI